| Literature DB >> 21390222 |
Mariama El Baroudi1, Davide Corà, Carla Bosia, Matteo Osella, Michele Caselle.
Abstract
BACKGROUND: The MYC transcription factors are known to be involved in the biology of many human cancer types. But little is known about the Myc/microRNAs cooperation in the regulation of genes at the transcriptional and post-transcriptional level. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 21390222 PMCID: PMC3048388 DOI: 10.1371/journal.pone.0014742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Construction of a catalogue of mixed Feed-Forward regulatory Loops having MYC as master regulator, in which all the regulatory interactions are experimentally validated.
a) Representation of a typical mixed single miRNA/Transcription Factor FFL having MYC as master regulator: MYC regulates a miRNA and together with it, a Joint Target protein-coding gene. According to the arrows direction, the mixed FFLs can be classified as incoherent (type I) or coherent (type II) circuits. b) Dataset used for the construction of the mixed FFLs catalogue.
Figure 2Properties of the mixed FFLs.
a) Graphical representation of the network obtained combining together all the MYC-centred mixed FFLs. MYC is depicted in green, nodes in red (diamonds) correspond to miRNAs, whereas the blue ones (ellipses) correspond to Joint Targets. Biological relationship between two nodes is represented as an edge (edges in green identify targets regulation by Myc, black edges evidence the miRNAs regulation by Myc and in red the targets regulated by miRNAs). b) Randomization results for the over-representation analysis of Myc induced mixed FFLs validated with low throughput experiments. We plotted the number of Joint Target genes obtained in the real Myc network, alongside the distributions (normalized histograms) of the number of Joint Target genes detected in the three randomization strategies adopted c) A few interesting examples of FFLs, having as Joint Target: (1)PTEN, (2)RB1 and (3)VEGF.
Functional Annotation Chart, performed using DAVID Bioinformatics tool.
| KEGG pathways | Genes | p-Value | Benjamini (corrected p-value) |
| Pathways in cancer | BCL2, E2F1, E2F3, CASP3, EGFR, VEGF, COL4A1, COL4A2, CD1, CDK6, p21, p27, CDKI2A, JUN, MET, MSH2, RAS, PTEN, RB1, TGFb2, MYC | 3.8E-11 | 1.8E-9 |
| Bladder cancer | E2F1, E2F3, EGFR, CD1, CDKI2A, CDKI1A, RAS, RB1, VEGF, MYC, THBS1 | 8.7E-12 | 8.4E-10 |
| Chronic myeloid leukemia | E2F1, E2F3, CD1, CDK6, CDKI1A, CDKI1B, CDKI2A, RAS, RB1, TGFb2, MYC | 3.7E-9 | 9.1E-8 |
| Small cell lung cancer | BCL2, E2F1, E2F3, COL4A1, COL4A2, CD1, CDKI1B, CDK6, PTEN, RB1, MYC | 1.2E-8 | 2.3E-7 |
| Melanoma | E2F1, E2F3, CD1, CDKI2A, CDKI1A, CDK6, EGFR, RAS, RB1, PTEN, MET | 2.2E-9 | 7.0E-8 |
| Glioma | E2F1, E2F3, CD1,CDKI2A, CDKI1A, CDK6, EGFR, RAS, RB1, PTEN | 1.3E-8 | 2.1E-7 |
We report the Gene Ontology (GO) Terms and KEGG pathways Over-represented among Joint Target Genes, performed using DAVID Bioinformatics tool. For each row the corresponding Benjamini (corrected for multiple testing) as well as the raw hypergeometric p-values are indicated.